CELL INTELLIGENCE · 肿瘤细胞治疗研究

新诊断弥漫大 B 细胞淋巴瘤的新兴治疗策略

Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma.

病例报告：CD20 双特异性抗体治疗后 CD19 CAR-T 细胞治疗后记忆形成的旁观者 T 细胞反应受损

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy.

淋巴瘤患者接受 Epcoritamab 治疗后发生结肠弯曲菌、巨细胞病毒和 SARS-CoV-2 三重感染

Triple Infections With Campylobacter coli, Cytomegalovirus, and SARS-CoV-2 in a Lymphoma Patient Treated With Epcoritamab.

Epcoritamab 在 CAR-T 治疗后复发 CD19-CD5+ 弥漫大 B 细胞淋巴瘤中的有效且安全给药

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

该病例凸显了 epcoritamab 联合减瘤治疗用于治疗 CAR-T 难治性 CD19 阴性 DLBCL 的潜力。

CD20/CD3 双特异性抗体在弥漫性大 B 细胞淋巴瘤中的开发及生物标志物

Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.

滤泡性淋巴瘤的 CAR-T 细胞与双特异性抗体治疗：近期进展与未来前景

Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: Recent advances and future prospects.

一例 CAR-T 细胞治疗伴持续性 CAR-T 细胞的 DLBCL 早期孤立性中枢神经系统复发的成功病例

A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.

B 细胞淋巴瘤中 CAR-T 细胞治疗后复发的治疗策略

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.

抗体药物和蘑菇来源 β-葡聚糖在 NK 细胞介导的抗非霍奇金 B 细胞淋巴瘤杀瘤活性中的抗肿瘤活性增强作用

Potentiation of Antitumor Activity by Antibody Drugs and Mushroom-Derived β-Glucans in Natural Killer Cell-Mediated Tumoricidal Activities against Non

东北及新潟地区老年原发性中枢神经系统淋巴瘤预后不良的临床病理危险因素：东北脑肿瘤研究组的多中心、回顾性、队列研究

Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a